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1Letters
Paraneoplastic Chorea Managed with Intravenous Amantadine
Nicholas Doher & Harsh V. Gupta*
Department of Neurology, Kansas University Medical Center, Kansas City, KS, USA 
To the Editor,
We have read the article entitled ‘Anti-CV2/CRMP5 paraneoplastic 
chorea effectively managed with intravenous amantadine’ with great 
interest.1 We would like to congratulate the authors for this unique case 
report and make some suggestions.
In the case report, there was decreased radionucleotide uptake 
on an fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane 
(FP-CIT PET) scan of  the bilateral striatum that corresponded to 
severe atrophy and increased T2 signal on the magnetic resonance 
imaging (MRI) of  the brain. This finding on FP-CIT PET imaging is 
expected given the structural abnormalities observed while conducting 
the MRI of  the brain and therefore adds little diagnostic value. 
FP-CIT PET and other dopamine transporter (DaT) scan techniques 
are approved to only differentiate essential tremor from neurodegener-
ative disorders.2 An abnormality on structural imaging will always give 
false-positive results on positron emission tomography (PET) or sin-
gle-photon emission computerized tomography (SPECT) and can lead 
to diagnostic confusion.3 There are many examples in literature of  
structural imaging abnormalities in the striatum with corresponding 
decreased uptake while using DaT scan techniques.4–8 It is important 
to stress that obtaining DaT scan imaging on a routine basis in patients 
diagnosed with structural abnormalities in the striatum upon conduct-
ing MRI is generally not indicated and can expose patients to unnec-
essary risk.
It should also be noted that there is some radiation exposure when a 
patient undergoes a DaT SPECT scan or PET scan. This can potentially 
increase the risk of  cancer, especially in the elderly population.9
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